Piperine mitigates behavioral impairments and provides neuroprotection against 3-nitropropinoic acid-induced Huntington disease-like symptoms
- 25 February 2020
- journal article
- research article
- Published by Taylor & Francis in Nutritional Neuroscience
- p. 1-10
Abstract
Background: Piperine (PIP) is a powerful anti-oxidant and anti-inflammatory alkaloid which has been widely used in the treatment of various pathological conditions. However, few studies have clearly discussed the protective effects and potential mechanism of PIP in different neurological diseases. The aim of this study was to investigate the neuroprotective effect of PIP against 3-nitropropioninc acid (3-NP) induced neurobehavioral, biochemical and histopathological alterations in animals. Methods: Adult male Wistar rats were randomly divided into three groups. Group 1, the vehicle administered control group, received normal saline (p.o.). Group 2 received 3-NP (20 mg/kg.b.wt., i.p.) for 4 consecutive days. Group 3 received PIP (10 mg/kg.b.wt., p.o.) twice daily for a period of 4 days, 30 min before and 6 h after the 3-NP injection. Upon termination of treatment schedule, behavioral experiments were performed to access the behavioral outcomes. The brain striatal tissue was used for the estimation of monoamine oxidase activity and serotonin level. In addition, astrocytes activation was observed by GFAP immunostaining. Results: Our results showed that 3-NP induced behavioral impairments are attenuated by PIP co-treatment. Next, the extent of neuronal loss and astrocytes activation was reduced in the striatal brain region in PIP treated rats. Finally, it was observed that PIP alleviated the behavioral, biochemical, immunohistochemical and histological alterations. Conclusion: The results of the current study reveal the neuroprotective competency of PIP against Huntington disease like symptoms in rats.Keywords
This publication has 47 references indexed in Scilit:
- Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone—a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar RatsJournal of Molecular Neuroscience, 2018
- SAP97‐mediated rescue of NMDA receptor surface distribution in a neuronal model of Huntington's diseaseHippocampus, 2018
- Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington’s disease-like symptoms in ratsBiomedicine & Pharmacotherapy, 2018
- Profilin-2 increased expression and its altered interaction with β-actin in the striatum of 3-nitropropionic acid-induced Huntington’s disease in ratsNeuroscience, 2014
- CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing HaplogroupThe American Journal of Human Genetics, 2009
- The molecular genetics of Huntington disease — a historyNature Reviews Genetics, 2005
- Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c releaseHuman Molecular Genetics, 2004
- The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegenerationNeuroRX, 2004
- Mitochondrial defect in Huntington's disease caudate nucleusAnnals of Neurology, 1996
- Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brainsNeurobiology of Disease, 1994